Institute of Medicine, Department of Internal Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden; Region Västra Götaland, Sahlgrenska University Hospital, Psychosis Clinic, Gothenburg, Sweden.
Institute of Medicine, Department of Internal Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Psychoneuroendocrinology. 2022 May;139:105710. doi: 10.1016/j.psyneuen.2022.105710. Epub 2022 Mar 5.
In epidemiological studies, higher thyroid hormone (TH) levels have been associated with lower brain volume and increased risk of Alzheimer's disease (AD) in elderly individuals. However, the relationships between serum THs and hippocampal atrophy rates have previously not been investigated.
A prospective study of patients with AD (n = 55), stable mild cognitive impairment (sMCI; n = 84) and healthy controls (n = 29) recruited at a single memory clinic. We investigated whether serum THs were associated with magnetic resonance imaging (MRI)-estimated hippocampal volumes at baseline and with longitudinal alterations, defined as annualized percent changes.
Serum levels of free triiodothyronine (FT3) and FT3/free thyroxine (FT4) ratio were reduced in AD and sMCI patients compared with the controls (p < 0.05). Hierarchical linear regression analyses showed that higher serum FT3/FT4 ratio was associated with greater baseline hippocampal volume in all study groups. Only in AD patients, higher serum FT4 was associated with lower baseline volume of the left hippocampus. Finally, exclusively in the AD group, higher serum levels of FT3 and FT3/FT4 ratio, and lower serum TSH levels, were associated with greater annual hippocampal volume loss.
In all study groups, FT3/FT4 ratio was related to baseline hippocampal volume. However, only in AD patients, higher levels of THs were associated with greater annual loss of hippocampal volume, suggesting that excessive TH levels exert a deleterious effect on the hippocampus in the presence of existing AD neuropathology.
在流行病学研究中,较高的甲状腺激素(TH)水平与老年人的脑体积较小和阿尔茨海默病(AD)风险增加有关。然而,血清 TH 与海马体萎缩率之间的关系以前尚未被研究过。
对在一个记忆诊所招募的 AD(n=55)、稳定轻度认知障碍(sMCI;n=84)和健康对照(n=29)患者进行前瞻性研究。我们调查了血清 TH 是否与基线时的磁共振成像(MRI)估计的海马体体积以及定义为年变化率的纵向变化有关。
与对照组相比,AD 和 sMCI 患者的血清游离三碘甲状腺原氨酸(FT3)和 FT3/甲状腺素(FT4)比值降低(p<0.05)。分层线性回归分析显示,在所有研究组中,较高的血清 FT3/FT4 比值与基线时较大的海马体体积相关。仅在 AD 患者中,较高的血清 FT4 与左侧海马体的较低基线体积相关。最后,仅在 AD 组中,较高的血清 FT3 和 FT3/FT4 比值以及较低的血清 TSH 水平与较大的年度海马体体积损失相关。
在所有研究组中,FT3/FT4 比值与基线时的海马体体积有关。然而,只有在 AD 患者中,较高的 TH 水平与海马体的更大年度损失有关,这表明在存在 AD 神经病理学的情况下,过高的 TH 水平对海马体有有害影响。